Cart
sales@molnova.com
2-hydroxy Flutamide
CAS No. 52806-53-8
2-hydroxy Flutamide( —— )
Catalog No. M20966 CAS No. 52806-53-8
2-hydroxy Flutamide is competitive inhibition of androgen receptor (AR) for the treatment of prostate cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 48 | In Stock |
|
| 5MG | 45 | In Stock |
|
| 10MG | 76 | In Stock |
|
| 25MG | 147 | In Stock |
|
| 50MG | 222 | In Stock |
|
| 100MG | 346 | In Stock |
|
| 200MG | 511 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Name2-hydroxy Flutamide
-
NoteResearch use only, not for human use.
-
Brief Description2-hydroxy Flutamide is competitive inhibition of androgen receptor (AR) for the treatment of prostate cancer.
-
Description2-hydroxy Flutamide is competitive inhibition of androgen receptor (AR) for the treatment of prostate cancer.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayEndocrinology/Hormones
-
TargetAndrogen Receptor (AR)
-
RecptorAndrogen Receptor
-
Research AreaCancer
-
IndicationProstate Cancer
Chemical Information
-
CAS Number52806-53-8
-
Formula Weight292.21
-
Molecular FormulaC11H11F3N2O4
-
Purity>98% (HPLC)
-
SolubilityDMSO:25mg/ml(85.5 mM)
-
SMILESCC(C)(O)C(=O)Nc1ccc([N+](=O)[O-])c(C(F)(F)F)c1
-
Chemical Name2-hydroxy-2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)propanamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Blobaum A L Byers F W Bridges T M et al. A Screen of Approved Drugs Identifies the Androgen Receptor Antagonist Flutamide and Its Pharmacologically Active Metabolite 2-Hydroxy-Flutamide as Heterotropic Activators of Cytochrome P450 3A In Vitro and In Vivo.[J]. Drug Metabolism & Disposition the Biological Fate of Chemicals 2015 43(11):1718.
molnova catalog
related products
-
Enobosarm
Enobosarm (GTx-024, MK-2866, Ostarine) is a selective androgen receptor modulator (SARM) for the treatment of conditions such as muscle wasting and osteoporosis.
-
RU 58841
A nonsteroidal, specific androgen receptor inhibitor; be useful for the topical treatment of androgen-dependent skin disorders such as acne, androgenetic alopecia and hirsutism.
-
VPC-13566
VPC-13566 is a BF3-specific small molecule, which effectively inhibited the androgen receptor transcriptional activity and displaced the BAG1L peptide from the BF3 pocket.
